Immatics wins NCI as partner to test cancer vaccine
Tuebingen - German Immatics biotechnologies heaps up partners for it cancer vaccine IMA950. The biotechnology company from Tuebingen announced that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR) of the US-National Cancer Institute. The agreement covers the clinical development of immatics’ therapeutic cancer vaccine IMA950 which is to be evaluated in the field of brain cancer, specifically glioblastoma, the most aggressive form of brain cancer. Under the terms of the agreement, CCR will sponsor and conduct a phase I trial of IMA950 which will be carried out at the National Institute of Health’s (NIH’s) Facility in Bethesda, Maryland. The phase I trial will evaluate IMA950 in stable or recurrence-free glioblastoma patients following standard radiochemotherapy with temozolomide.
That's already the second high-level partner for IMA950. In February 2010 immatics signed a contract with Cancer Research UK for the clinical development of IMA950 in glioblastoma. The Cancer Research UK sponsored study will treat newly diagnosed patients with IMA950 in combination with radio-chemotherapy while this study at the NCI will treat patients after successful radio-chemotherapy with standalone IMA950. "Our ability to secure two such highly regarded collaborators to advance IMA950 into the clinic demonstrates the significant interest in immatics’ novel therapeutic vaccines", said Paul Higham, CEO of Immatics.